Fertility and Sterility
Volume 82, Issue 1 , Pages 1-12, July 2004

Why consider vaginal drug administration?

  • Nancy J Alexander, Ph.D.

      Affiliations

    • UMD–New Jersey Medical School, Newark, New Jersey, USA
    • Organon Pharmaceuticals USA, Inc., Roseland, New Jersey, USA
    • Corresponding Author InformationReprint requests: Nancy J. Alexander, Ph.D., Organon Pharmaceuticals USA, Inc., 56 Livingston Avenue, Roseland, New Jersey 07068, USA (FAX: 973-325-4699).
    • ,
  • Edward Baker, M.D.

      Affiliations

    • Organon Pharmaceuticals USA, Inc., Roseland, New Jersey, USA
    • ,
  • Marc Kaptein, M.D.

      Affiliations

    • Organon International, Inc., Roseland, New Jersey, USA
    • ,
  • Ulrich Karck, M.D.

      Affiliations

    • Stuttgart Women's Hospital, Stuttgart, Germany
    • ,
  • Leslie Miller, M.D.

      Affiliations

    • University of Washington School of Medicine, Seattle, Washington, USA
    • ,
  • Edio Zampaglione, M.D.

      Affiliations

    • Organon Pharmaceuticals USA, Inc., Roseland, New Jersey, USA

Received 24 October 2003; received in revised form 4 January 2004; accepted 4 January 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0015-0282(04)00509-6

doi:10.1016/j.fertnstert.2004.01.025

Fertility and Sterility
Volume 82, Issue 1 , Pages 1-12, July 2004

Article Tools

* Image Usage & Resolution